235 related articles for article (PubMed ID: 37457723)
1. PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer.
Akbari B; Soltantoyeh T; Shahosseini Z; Jadidi-Niaragh F; Hadjati J; Brown CE; Mirzaei HR
Front Immunol; 2023; 14():1209572. PubMed ID: 37457723
[TBL] [Abstract][Full Text] [Related]
2. Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.
Francica BJ; Holtz A; Lopez J; Freund D; Chen A; Wang D; Powell D; Kipper F; Panigrahy D; Dubois RN; Whiting CC; Prasit P; Dubensky TW
Cancer Res Commun; 2023 Aug; 3(8):1486-1500. PubMed ID: 37559947
[TBL] [Abstract][Full Text] [Related]
3. PGE
Thumkeo D; Punyawatthananukool S; Prasongtanakij S; Matsuura R; Arima K; Nie H; Yamamoto R; Aoyama N; Hamaguchi H; Sugahara S; Takeda S; Charoensawan V; Tanaka A; Sakaguchi S; Narumiya S
Cell Rep; 2022 Jun; 39(10):110914. PubMed ID: 35675777
[TBL] [Abstract][Full Text] [Related]
4. T cell-intrinsic prostaglandin E
Lee J; Aoki T; Thumkeo D; Siriwach R; Yao C; Narumiya S
J Allergy Clin Immunol; 2019 Feb; 143(2):631-643. PubMed ID: 29935220
[TBL] [Abstract][Full Text] [Related]
5. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism.
Schmidt A; Sinnett-Smith J; Young S; Chang HH; Hines OJ; Dawson DW; Rozengurt E; Eibl G
Surgery; 2017 Jun; 161(6):1570-1578. PubMed ID: 28222855
[TBL] [Abstract][Full Text] [Related]
6. EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells.
Cuenca-Escalona J; Subtil B; Garcia-Perez A; Cambi A; de Vries IJM; Flórez-Grau G
Front Immunol; 2024; 15():1355769. PubMed ID: 38343540
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells.
Hsu HH; Lin YM; Shen CY; Shibu MA; Li SY; Chang SH; Lin CC; Chen RJ; Viswanadha VP; Shih HN; Huang CY
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28587064
[TBL] [Abstract][Full Text] [Related]
8. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.
Holt DM; Ma X; Kundu N; Collin PD; Fulton AM
J Immunother; 2012; 35(2):179-88. PubMed ID: 22306906
[TBL] [Abstract][Full Text] [Related]
9. PGE2-EP4 signaling steers cDC2 maturation toward the induction of suppressive T-cell responses.
Cuenca-Escalona J; Flórez-Grau G; van den Dries K; Cambi A; de Vries IJM
Eur J Immunol; 2024 Mar; 54(3):e2350770. PubMed ID: 38088451
[TBL] [Abstract][Full Text] [Related]
10. Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists.
Bödder J; Kok LM; Fauerbach JA; Flórez-Grau G; de Vries IJM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674907
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.
Chang HH; Young SH; Sinnett-Smith J; Chou CE; Moro A; Hertzer KM; Hines OJ; Rozengurt E; Eibl G
Am J Physiol Cell Physiol; 2015 Nov; 309(10):C639-49. PubMed ID: 26310818
[TBL] [Abstract][Full Text] [Related]
12. Metabolic regulation by prostaglandin E
Robb CT; Zhou Y; Felton JM; Zhang B; Goepp M; Jheeta P; Smyth DJ; Duffin R; Vermeren S; Breyer RM; Narumiya S; McSorley HJ; Maizels RM; Schwarze JKJ; Rossi AG; Yao C
Allergy; 2023 Mar; 78(3):714-730. PubMed ID: 36181709
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells.
Kay LJ; Gilbert M; Pullen N; Skerratt S; Farrington J; Seward EP; Peachell PT
Clin Exp Allergy; 2013 Jul; 43(7):741-51. PubMed ID: 23786281
[TBL] [Abstract][Full Text] [Related]
14. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E
Ohkura N; Yoshiba K; Yoshiba N; Oda Y; Edanami N; Ohshima H; Takenaka S; Okiji T; Noiri Y
J Endod; 2023 Apr; 49(4):410-418. PubMed ID: 36758673
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.
Bonfill-Teixidor E; Otxoa-de-Amezaga A; Font-Nieves M; Sans-Fons MG; Planas AM
J Neuroinflammation; 2017 Jan; 14(1):3. PubMed ID: 28086956
[TBL] [Abstract][Full Text] [Related]
17. Concerted EP2 and EP4 Receptor Signaling Stimulates Autocrine Prostaglandin E
Mangelsen E; Rothe M; Schulz A; Kourpa A; Panáková D; Kreutz R; Bolbrinker J
Cells; 2020 May; 9(5):. PubMed ID: 32438662
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E
Goepp M; Crittenden S; Zhou Y; Rossi AG; Narumiya S; Yao C
Immunology; 2021 Dec; 164(4):777-791. PubMed ID: 34529833
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation.
Mo C; Zhao R; Vallejo J; Igwe O; Bonewald L; Wetmore L; Brotto M
Cell Cycle; 2015; 14(10):1507-16. PubMed ID: 25785867
[TBL] [Abstract][Full Text] [Related]
20. Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors.
Corminboeuf O; Diethelm S; Zumbrunn C; Lyothier I; Niggli N; Gnerre C; Jeay S; Lehembre F; Boss C
ChemMedChem; 2024 Jan; 19(2):e202300606. PubMed ID: 37983645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
